Debate: Optimal Second-Line Therapy in Pancreatic Neuroendocrine Tumors (pNET): Capecitabine + Temozolomide (CAPTEM) vs. Peptide Receptor Radionuclide Therapy (PRRT). - Peptide Receptor Radionuclide Therapy (PRRT)

Debate Speaker(s)

• 

  Thorvardur R. Halfdanarson, MD

  Mayo Clinic
  Mayo Clinic College of Medicine and Science